Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank
Mandate

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

July 18, 2025 Banking and Finance

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).

The financing is structured as a venture debt loan – a form of growth financing tailored to innovative companies. It is provided under the InvestEU programme, which supports the EU’s green transition and efforts to spur innovation, industrial resilience and sustainable economic growth. The EIB financing will support development and commercialization of a fiber-based technology developed by PulPac as an alternative to single-use plastics.

The Vinge team consisted of Kristian Ford (responsible partner), Henrik Ossborn and Agaton Lindgren (banking and finance).

Read more in the press release from PulPac

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026